平台已收录预计检索 <10 秒
The Lancet HIV Commission on ageing and HIV: a global perspective
查看已审核书目、规范引用与获取指引。下载与积分规则登录后查看。
文献信息
- 题目
- The Lancet HIV Commission on ageing and HIV: a global perspective
- 作者
- Amy C Justice, Keri N Althoff, A Mark Clarfield, Brenda Crabtree Ramirez, Nathan Ford, Mary-Anne Hartley, Jepchirchir Kiplagat, Grace C Y Lui, Aggrey S Semeere, Marco Vitoria, Stephen Watiti, Tristan J Barber, Till W Barnighausen, Marta Boffito, Mark Brennan-Ing, Jessica Castilho, Stephen R Connor, Claudia Cortes, Giovanni Guaraldi, Meredith Greene, Beatriz Grinsztejn, Catherine Godfrey, Workegegnehu Hailu, Virgilio A Hernandez Ruiz, Javier Hourcade Bellocq, Vanessa Johnson, John Joska, Parastu Kasaie, Oageng Moseki, Nadia Naous, Joel Negin, Daniel Ochieng, Dorothy Onyango, Nicoletta Policek, Yvette Raphael, Julia Rohr, Anat Rosenthal, Enid J Schatz, Melissa C Schnure, Kailey R Seiler, Tinei Shamu, Mikaela Smit, Kristen A Stafford, Omar Sued, Andrew Tan, Jaques D du Toit, Sandra Wagner Cardoso
- 发表年份
- 2026
- 期刊 / 来源
- The Lancet HIV
- 出版社
- Elsevier
- 文献类型
- 学术文献
- 平台记录更新
- 2026-09-15 16:22:28
本页由 Scihuhuan.com 学术互换提供文献检索、引用与获取指引;论文版权和出版身份归原出版方。
引用格式
同来源相关文献
Time to HIV rebound after infusion of long-acting broadly neutralising antibodies 3BNC117-LS and 10-1074-LS and analytical treatment interruption (the RIO trial): a double-blind, randomised, placebo-controlled trial2026 · The Lancet HIVDolutegravir plus boosted darunavir versus recommended standard-of-care antiretroviral regimens in people with HIV-1 for whom recommended first-line non-nucleoside reverse transcriptase inhibitor therapy has failed (D2EFT): an open-label, randomised, phase 3b/4 trial2024 · The Lancet HIVSafety, tolerability, and acceptability of long-acting injectable cabotegravir for HIV prevention in cisgender female adolescents (HPTN 084-01): a single-arm, open-label, phase 2b trial2025 · The Lancet HIVHIV funders need to shift power and resources to communities2023 · The Lancet HIVThe case for pre-exposure prophylaxis in prison settings2023 · The Lancet HIVSelf-control for harm reduction in chemsex2023 · The Lancet HIV